CJC-1295 (with and without DAC) Half-Life & Pharmacokinetics
Research-only pharmacokinetic profile of CJC-1295: serum half-life, Tmax, route comparisons, clearance and bioavailability — curated from published preclinical and clinical PK literature.
CJC-1295 (with and without DAC) Half-Life & Pharmacokinetics — Research Guide (2026)
Research-use only. This guide summarises published pharmacokinetic (PK) data on CJC-1295 (with and without DAC) for laboratory research and educational reference. Nothing on this page is medical advice or a recommendation for human use.
CJC-1295 (with and without DAC) is classified as a GHRH analogue; with-DAC variant uses Drug Affinity Complex technology. Its pharmacokinetic profile — serum half-life, time to peak (Tmax), route-of-administration behaviour, clearance pathway and bioavailability — directly shapes how researchers schedule dosing, interpret PD endpoints and design steady-state experiments.
At-a-Glance Pharmacokinetics
| Parameter | CJC-1295 | | --- | --- | | Classification | GHRH analogue; with-DAC variant uses Drug Affinity Complex technology | | Serum half-life | Without DAC (Mod GRF 1-29): ~30 minutes. | | Tmax | No-DAC: ~15 minutes. | | Validated routes | Subcutaneous administration is standard in the published literature for both DAC and no-DAC variants. | | Bioavailability | Subcutaneous bioavailability ~50–70% (no-DAC) and >80% (DAC) in published PK datasets. | | Clearance | No-DAC: rapid enzymatic clearance. |
Serum Half-Life
Without DAC (Mod GRF 1-29): ~30 minutes. With DAC (albumin-bound): published terminal half-life of ~6–8 days, supporting weekly dosing in research protocols.
The functional implication is that steady-state PK is reached at approximately 4–5 half-lives. For CJC-1295, that informs how quickly researchers can expect plasma exposure to stabilise across repeat dosing.
Time to Peak (Tmax)
No-DAC: ~15 minutes. With DAC: serum GH and IGF-1 elevations persist for 6–8 days post-dose in published clinical PK studies.
Tmax is the parameter that most directly governs acute pharmacodynamic readouts. For GH-axis peptides this dictates blood-sampling timing for stimulated GH; for incretin analogues it shapes the post-prandial glucose challenge window.
Routes of Administration
Subcutaneous administration is standard in the published literature for both DAC and no-DAC variants.
Bioavailability across routes: Subcutaneous bioavailability ~50–70% (no-DAC) and >80% (DAC) in published PK datasets.
Clearance & Metabolism
No-DAC: rapid enzymatic clearance. With-DAC: albumin binding extends circulation; cleared via normal albumin turnover and renal handling of fragments.
Key Pharmacokinetic Takeaways
- Two distinct pharmacokinetic profiles depending on the DAC linker — never substitute one for the other
- DAC variant produces sustained 'GH bleed' rather than pulsatile release; no-DAC preserves pulsatility
- Weekly dosing of DAC variants is supported by the 6–8 day terminal half-life in published human PK
- Frequently stacked with ipamorelin in pulsatile-stimulation research protocols
Frequently Asked Questions
What is the half-life of CJC-1295? Without DAC (Mod GRF 1-29): ~30 minutes. With DAC (albumin-bound): published terminal half-life of ~6–8 days, supporting weekly dosing in research protocols.
How quickly does CJC-1295 reach peak concentration? No-DAC: ~15 minutes. With DAC: serum GH and IGF-1 elevations persist for 6–8 days post-dose in published clinical PK studies.
Which routes of administration are validated in published research? Subcutaneous administration is standard in the published literature for both DAC and no-DAC variants.
Does CJC-1295 accumulate with repeat dosing? No-DAC: rapid enzymatic clearance. With-DAC: albumin binding extends circulation; cleared via normal albumin turnover and renal handling of fragments. Steady-state is typically reached at 4–5 half-lives in published multi-dose studies.
Is oral bioavailability meaningful for CJC-1295? Subcutaneous bioavailability ~50–70% (no-DAC) and >80% (DAC) in published PK datasets.
Related Research
- Reconstitution & storage protocols — see the CJC-1295 reconstitution guide for vial handling that preserves the PK profile described above.
- Dosing protocols research — see the CJC-1295 dosing protocols article for how PK parameters translate into scheduling decisions.
- Mechanism of action — see the CJC-1295 mechanism guide for the receptor-level basis of the PD effects driven by the PK profile.
---
*Sources cited inline are drawn from published preclinical and clinical pharmacokinetic literature. This article is for laboratory research and educational use only and does not constitute medical advice.*
Related Research Articles
Epitalon Half-Life & Pharmacokinetics
Research-only pharmacokinetic profile of Epitalon: serum half-life, Tmax, route comparisons, clearance and bioavailability — curated from published preclinical and clinical PK literature.
MOTS-c Half-Life & Pharmacokinetics — Research Guide (2026)
Research-only pharmacokinetic profile of MOTS-c: serum half-life, Tmax, route comparisons, clearance and bioavailability — curated from published preclinical and clinical PK literature.
Tirzepatide Half-Life & Pharmacokinetics
Research-only pharmacokinetic profile of Tirzepatide: serum half-life, Tmax, route comparisons, clearance and bioavailability — curated from published preclinical and clinical PK literature.
Semaglutide Half-Life & Pharmacokinetics
Research-only pharmacokinetic profile of Semaglutide: serum half-life, Tmax, route comparisons, clearance and bioavailability — curated from published preclinical and clinical PK literature.
Tesamorelin Half-Life & Pharmacokinetics
Research-only pharmacokinetic profile of Tesamorelin: serum half-life, Tmax, route comparisons, clearance and bioavailability — curated from published preclinical and clinical PK literature.
Sermorelin (GHRH 1-29) Half-Life & Pharmacokinetics
Research-only pharmacokinetic profile of Sermorelin: serum half-life, Tmax, route comparisons, clearance and bioavailability — curated from published preclinical and clinical PK literature.
Related Research Materials
Parent Research Hubs
Recombinant human growth hormone (somatropin) is one of the most extensively studied endocrine compounds in the published literature. This hub aggregates Ares Research's HGH reference material — receptor signalling, dose-response, body composition, longevity, and head-to-head comparisons with peptide GH-axis modulators.
Explore hub →CJC-1295 is a tetrasubstituted GHRH(1-29) analog studied in two forms: with a drug-affinity complex (DAC) that binds serum albumin and extends half-life to days, and without DAC (also called Mod GRF 1-29) for short, pulsatile GH stimulation.
Explore hub →Neutral, moderated research discussion. Laboratory use only.
More compound guides, hubs, and educational research materials.